Skip to main navigation Skip to search Skip to main content

Mechanistic insights into zearalenone-accelerated colorectal cancer in mice using integrative multi-omics approaches

  • Emily Kwun Kwan Lo (Co-first Author)
  • , Xiuwan Wang (Co-first Author)
  • , Pui-Kei Lee
  • , Ho-Ching Wong
  • , Jetty Chung-Yung Lee
  • , Carlos Gómez-Gallego
  • , Danyue Zhao*
  • , Hani El-Nezami
  • , Jun Li*
  • *Corresponding author for this work

Research output: Journal Publications and ReviewsRGC 21 - Publication in refereed journalpeer-review

84 Downloads (CityUHK Scholars)

Abstract

Zearalenone (ZEA), a secondary metabolite of Fusarium fungi found in cereal-based foods, promotes the growth of colon, breast, and prostate cancer cells in vitro. However, the lack of animal studies hinders a deeper mechanistic understanding of the cancer-promoting effects of ZEA. This study aimed to determine the effect of ZEA on colon cancer progression and its underlying mechanisms. Through integrative analyses of transcriptomics, metabolomics, metagenomics, and host phenotypes, we investigated the impact of a 4-week ZEA intervention on colorectal cancer in xenograft mice. Our results showed a twofold increase in tumor weight with the 4-week ZEA intervention. ZEA exposure significantly increased the mRNA and protein levels of BEST4, DGKB, and Ki67 and the phosphorylation levels of ERK1/2 and AKT. Serum metabolomic analysis revealed that the levels of amino acids, including histidine, arginine, citrulline, and glycine, decreased significantly in the ZEA group. Furthermore, ZEA lowered the alpha diversity of the gut microbiota and reduced the abundance of nine genera, including Tuzzerella and Rikenella. Further association analysis indicated that Tuzzerella was negatively associated with the expression of BEST4 and DGKB genes, serum uric acid levels, and tumor weight. Additionally, circulatory hippuric acid levels positively correlated with tumor weight and the expression of oncogenic genes, including ROBO3, JAK3, and BEST4. Altogether, our results indicated that ZEA promotes colon cancer progression by enhancing the BEST4/AKT/ERK1/2 pathway, lowering circulatory amino acid concentrations, altering gut microbiota composition, and suppressing short chain fatty acids production. © 2023 The Author(s).
Original languageEnglish
Pages (from-to)1785-1796
JournalComputational and Structural Biotechnology Journal
Volume21
Online published28 Feb 2023
DOIs
Publication statusPublished - 2023

Funding

This study was supported by the Shenzhen Basic Research Program (JCYJ20190808182402941), Guangdong Basic and Applied Research Major Program (2019B030302005), Collaborative Research Fund (C7013-19GF) in Hong Kong, City University of Hong Kong Internal Grant (7005756, 9678247, 9680310), and PolyU Startup Fund (1-BE3H).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Research Keywords

  • Zearalenone
  • Colon cancer
  • RNA-Seq
  • Gut microbiota
  • Metabolomics
  • Multi-omics

Publisher's Copyright Statement

  • This full text is made available under CC-BY-NC-ND 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/

RGC Funding Information

  • RGC-funded

Fingerprint

Dive into the research topics of 'Mechanistic insights into zearalenone-accelerated colorectal cancer in mice using integrative multi-omics approaches'. Together they form a unique fingerprint.

Cite this